CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CFGFR2MutationPredictiveSupportsSensitivity/ResponseCholangiocarcinomaInfigratinibNogova et al., 2017
CFGFR2::vFusion OR FGFR2::? FusionPredictiveSupportsSensitivity/ResponseCholangiocarcinomaInfigratinibNogova et al., 2017
CPTENMutationDiagnosticSupportsPositiveGlioblastomaRasheed et al., 1997
BEGFRExpressionPredictiveSupportsSensitivity/ResponseChordomaLapatinibStacchiotti et al., 2013
DERBB2V773APredictiveSupportsSensitivity/ResponseCancerLapatinibKancha et al., 2011
DERBB2N857SPredictiveSupportsSensitivity/ResponseCancerLapatinibKancha et al., 2011
DERBB2H878YPredictiveSupportsSensitivity/ResponseCancerLapatinibKancha et al., 2011
CFGFR1AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerFexagratinibPearson et al., 2016
CERBB2OverexpressionPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaLapatinibSeim et al., 2017
BGNASc.393T>CPredictiveSupportsResistanceLung Non-small Cell CarcinomaGefitinib,ErlotinibHong et al., 2014
BKRASG12APredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
BKRASG12APredictiveSupportsResistanceMultiple MyelomaMelphalanGreco et al., 2009
DKRASG12APredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2000
DKRASG12APredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2002
DKRASG12APredictiveSupportsResistanceMultiple MyelomaMelphalanHoang et al., 2006
BIDH1R132PredictiveSupportsSensitivity/ResponseHigh Grade GliomaSunitinib,BevacizumabLv et al., 2011
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibO'Brien et al., 2010
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
BPTENLossPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabRazis et al., 2011
CPIK3CAE545KPredictiveDoes Not SupportResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPI103Zou et al., 2009
BPIK3CARare MutationPrognosticSupportsBetter OutcomeBreast CancerKalinsky et al., 2009
BPTENLossPredictiveSupportsResistanceBreast CancerTrastuzumabRazis et al., 2011
DPTENLossPredictiveDoes Not SupportSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
BPIK3CAH1047RPrognosticSupportsBetter OutcomeBreast CancerKalinsky et al., 2009
BPIK3CAH1047RPrognosticSupportsBetter OutcomeBreast CancerMaruyama et al., 2007
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
BPIK3CAE545KPrognosticSupportsPoor OutcomeRectum CancerHe et al., 2009
CEGFRT790MPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaOsimertinibPlanchard et al., 2015
DEGFRT790MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaNeratinibShimamura et al., 2006
DEGFRT790MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinibLi et al., 2008
DEGFRT790MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinibCha et al., 2012
DEGFRT790MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCanertinibLi et al., 2008
DBCR::ABL1Fusion AND ABL1 F359VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
CBCR::ABL1Fusion AND ABL1 F359VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
CBCR::ABL1Fusion AND ABL1 F359VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibO'Hare et al., 2005
DKRASG13DPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,DactolisibMigliardi et al., 2012
CNRASQ61RPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
CPIK3CAQ546KPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
BNRASMutationPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
DKRASG12CPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,DactolisibMigliardi et al., 2012
BKRASG12DPredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
BKRASMutationPredictiveSupportsResistanceLung Non-small Cell CarcinomaErlotinibRamalingam et al., 2011
DKRASG12DPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2000
DKRASG12DPredictiveSupportsResistanceMultiple MyelomaMelphalanHoang et al., 2006
BKRASG12CPredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
DKRASG12CPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2000
DKRASG12CPredictiveSupportsResistanceMultiple MyelomaMelphalanHoang et al., 2006
CKRASG12VPredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
Page 74 of 96
PreviousNext